A nti-tumor necrosis factor (anti-TNF) therapy has revolutionized the management of patients with inflammatory bowel disease (IBD). 1 In multiple randomized controlled trials, both infliximab (IFX) and adalimumab (ADA) have demonstrated efficacy in reducing symptom burden, [2] [3] [4] inducing and maintaining clinical remission, decreasing the risk of hospitalization and surgical resection, 5, 6 and promoting mucosal healing in both Crohn's disease (CD) 7 and ulcerative colitis (UC). 8 Moreover, the use of anti-TNF drugs has also been advocated to reduce corticosteroid dependence. 2, 9 Corticosteroid use remains highly prevalent in IBD management, despite the known risk of significant side effects and complications in both the short-term and long-term. 10 We recently reported that there has been no reduction in the cumulative dose of corticosteroids on average across the population of IBD between 1995 and 2010, despite the increasing prevalence of immunomodulatory (IM) use among persons with IBD over that time. 10 However, we have not specifically assessed corticosteroid requirements in persons who ultimately use anti-TNF drugs. The expedient introduction of corticosteroid-sparing agents such as anti-TNF drugs in persons with corticosteroid dependence is an important metric of quality of care in persons with IBD. Therefore, we sought to evaluate temporal changes in the patterns of anti-TNF use, combination IM therapy at the time of anti-TNF initiation, and in the burden of corticosteroid use before anti-TNF use.
Methods

Data Source
We used the University of Manitoba Inflammatory Bowel Disease Epidemiologic Database, 11 which contains demographics, inpatient hospital stays, outpatient visits, and drug use for all persons in Manitoba meeting a wellvalidated administrative case definition of IBD from 1984 to 2014. Nearly 100% of residents of Manitoba are registered with Manitoba Health, which is the single insurer for all medical services. A full description of the methodology used to identify IBD patients has been previously published. 11 Data on all outpatient medications dispensed to residents of Manitoba, including drug name, strength, doses dispensed, and anticipated duration of therapy, have been captured since 1995. The University of Manitoba Inflammatory Bowel Disease Epidemiologic Database does not contain endoscopic or histologic data, and thus the extent of disease and endoscopic and/or histologic severity cannot be determined. The University of Manitoba Inflammatory Bowel Disease Epidemiologic Database does not contain information on symptom burden, health-related quality of life, or personal behaviors (diet, tobacco use, exercise).
Anti-Tumor Necrosis Factor Use
IFX and ADA are the only anti-TNF agents approved for the management of IBD in Canada. IFX was first approved by Health Canada for CD in 2001 and for UC in 2007; ADA was approved by Health Canada in 2006 for CD and in 2011 for UC. Manitoba Health policy restricts access to anti-TNF therapy to persons who had either not responded to or developed intolerance to IMs such as azathioprine or methotrexate; however, exceptions are regularly made on request. There are no specific provincial formulary restrictions regarding the dose of anti-TNF drug or on the frequency of dispensation. Although the provincial drug databases do not capture medications dispensed by inpatient pharmacies, short-term inpatients who are using anti-TNFs generally have them dispensed by an outpatient pharmacy and brought into hospital to be administered. We were not able to track any dispensations of anti-TNF agents that were provided in a clinical trial.
Study Population
We identified all persons with IBD who received at least 1 dose of anti-TNF therapy. Analyses that evaluated time from diagnosis to initiation of anti-TNF therapy included only incident cases of IBD diagnosed after anti-TNF therapy first became available in Manitoba (August 21, 2001 ). We assumed a case of IBD to be incident if they had at least 3 years of continuous registration with Manitoba Health where no IBD-related health care contacts occurred; the date of the first IBD contact was assumed to be the date of IBD diagnosis. In analyses of corticosteroid and/or IM use before anti-TNF initiation, we included only incident cases of IBD diagnosed after drug use data first became available (April 1, 1996).
We excluded all IBD patients with potential competing indications for anti-TNF therapy and a history of solid organ transplant (because they are often on chronic corticosteroids), defined as having at least 2 physician contacts coded for these diagnoses before initiation of anti-TNF therapy.
Point and Cumulative Prevalence
The point and cumulative prevalence of anti-TNF use among all persons with IBD on all dates between 2001 (the year of anti-TNF introduction in Manitoba) and 2014 was determined for the entire IBD population. Point prevalence was defined as having an anti-TNF dispensation in the previous 90 days, whereas cumulative prevalence was defined as having a history of anti-TNF dispensation at any time after IBD diagnosis.
Time to First Use of Anti-Tumor Necrosis Factor Drugs
We performed survival analyses to assess the time from IBD diagnosis until initial anti-TNF drug dispensation. Subjects were censored at death, outmigration, or end of follow-up (March 31, 2014).
Corticosteroid Use Before Anti-Tumor Necrosis Factor Dispensation
We assessed oral corticosteroid use before anti-TNF therapy in a number of ways. Within the cohort of all incident IBD who received anti-TNF therapy, we determined the cumulative dose of corticosteroids in the year before starting anti-TNFs and in the span between initial IBD diagnosis and first receipt of anti-TNFs. We also determined the proportion of anti-TNF users with a history of corticosteroid dependence before beginning anti-TNF therapy, defined as receipt of oral systemic corticosteroids of greater than 2000 mg prednisone used within any 12-month period spread over !2 separate dispensations. Corticosteroid doses were converted to prednisone equivalents by using a well-accepted conversion table. 12 We did not include the use of oral budesonide.
Immunomodulator Use Before Anti-Tumor Necrosis Factor Dispensation
We assessed the use of IM medications (6-mercaptopurine, azathioprine, and methotrexate) in the year before anti-TNF use. We determined the proportion with an active dispensation of IM medication (defined as a dispensation of an IM of sufficient duration to overlap initiation of anti-TNF) at the time of anti-TNF initiation. Of the anti-TNF users with active IM use at the time of anti-TNF dispensation, we estimated the proportion who intended to continue IM therapy after anti-TNF initiation, defined as (1) dispensation of an IM in the 60 days after initial anti-TNF dispensation or (2) IM medication use for the first time within the 30 days before the start of anti-TNF therapy. We also identified all instances of first IM use among incident cases of IBD and performed survival analysis by using Kaplan-Meier estimators to assess time from initial IM dispensation to anti-TNF initiation.
Inflammatory Bowel Disease-related Hospitalization and Surgery Before Anti-Tumor Necrosis Factor Use
We determined the frequency of IBD-related hospitalizations with at least 1 overnight stay and surgeries between the date of IBD diagnosis and the initial dispensation of anti-TNF. A hospitalization was considered to be IBD-related if either CD or UC appeared in the first 3 diagnostic positions on the hospital discharge abstract. IBD-related surgery was defined as any intestinal resection appearing either in the procedure list in the hospital discharge abstract or in the physician's billing database.
Determination of Disease Severity
We stratified all persons in the cohort according to the severity of their initial course of disease, ie, during the first 12 months of disease after diagnosis. We defined a person as having a severe initial course of disease if there were either 2 or more IBD-related hospitalizations or >1000 mg corticosteroids dispensed in the first 12 months after diagnosis. Persons with use of anti-TNF medications in the first 12 months of diagnosis were excluded, as were subjects with 12 months or fewer of post-diagnosis follow-up. Survival analysis was performed to determine the rates of anti-TNF exposure between those persons with and without a severe initial course of IBD.
Statistical Analysis
All survival analyses were performed by using nonparametric Kaplan-Meier estimators, with subjects censored at death, outmigration from the province, or the end of database follow-up (ie, March 31, 2014). All analyses were performed separately for persons with CD and UC.
The We also performed comparisons within these survival analyses by using other stratifications, including sex, age group at diagnosis (<18, 18-39, !40 years), as well as comparisons between CD and UC. Differences in event-free survival time were compared by using the log-rank test, with the Sidak correction for multiple comparisons when appropriate. 13 We used the Kruskal-Wallis-Dunn test to compare nonnormally distributed data, specifically those outcomes related to cumulative corticosteroid dosing in the year before anti-TNF initiation. 14 It is noted that people diagnosed in the different eras will have differing lengths of person-time available for follow-up, which means that persons diagnosed in later eras will have less measurable time to accrue corticosteroid exposure. To avoid the biasing effect of this, we limited this analysis to the same fixed percentage of all persons in each era who went on to receive anti-TNF therapy in each of the 3 eras for CD and the later 2 eras for UC. That percentage was defined as the number of persons diagnosed in that era who received anti-TNFs divided by the total number of persons diagnosed in that era. This resulted in our comparison of the first 23.0% of persons of CD and the first 9.3% of persons with UC who received anti-TNF each era.
This research was approved by the University of Manitoba Health Research Ethics Board, and access to data was granted by the Manitoba Health Information Privacy Committee.
Results
Overall, there were 950 persons with IBD who received anti-TNF therapy; details of this cohort are shown in Table 1 . The point prevalence gradually increased for both IFX and ADA over time, with IFX use being more prevalent than ADA use (Figures 1, 2) . By the end of the study period, 20.4% and 6.0% of persons with CD and UC, respectively, had been exposed to an anti-TNF at any time, with 14.2% of CD and 4.1% of UC having received an anti-TNF drug in the previous 90 days. At the end of the study period, there was no significant difference in the cumulative prevalence of anti-TNF use between the sexes (22.9% men vs 18.6% women [CD], 6.5% men vs 5.6% women [UC]). Anti-TNF use was much more common in younger IBD cohorts, with 38.5% of persons with CD diagnosed when younger than age 18 having had anti-TNF exposure compared with 22.2% aged 18-39 and 10.7% older than age 40.
Among incident cases of IBD who were diagnosed during the era of anti-TNF availability, 7.3%, 14.5%, and 23.4% of persons with CD and 2.2%, 4.4%, and 7.8% of persons with UC were exposed to anti-TNF within 1, 2, and 5 years of disease diagnosis, respectively (Figure 3 ). There was no difference between the sexes in terms of likelihood of having an initial dispensation of anti-TNF in the first 5 years after diagnosis (23.6% men vs 23.1% women with CD; 8.4% men vs 7.2% women with UC; P > .2).
Severity
A total of 2791 persons (1222 CD, 1569 UC) were diagnosed with IBD in the era of anti-TNF availability, of whom 447 eventually received anti-TNF. Persons with indicators of severe disease in the first year after diagnosis were more likely to receive anti-TNF therapy in the subsequent years than those without (Supplementary Figure 1) . By the end of the fifth year after diagnosis, 25.7% of patients with severe CD and 12.1% of patients with severe UC had been prescribed an anti-TNF compared with those with mild disease (12.7% of CD, 2.5% of UC).
Immunomodulator Use
Overall, 91.5% of CD and 87.1% of UC patients had a history of IM use before anti-TNF initiation, with 56.5% of CD and 46.0% of UC patients being active users of IMs at the time of onset of anti-TNF therapy. Of these active users, 65% and 59% of patients with CD and UC, respectively, had evidence of continuing use of IM after anti-TNF initiation. The median time between first receiving an IM drug and starting anti-TNF therapy was 481 days for CD (interquartile range [IQR], 202-1329) and 447 days for UC (IQR, 181-1315; P > .2 for CD vs UC). Among persons with CD who went on to receive anti-TNF, persons diagnosed when younger than the age of 18 had a longer time from first IM to first anti-TNF than those aged 18- 
Corticosteroid Use and Dependence Before Anti-Tumor Necrosis Factor Use
The median dose of corticosteroids dispensed in the year before anti-TNF initiation was higher among persons with UC than for CD (2865 mg vs 830 mg of prednisone equivalents, P < .0001), as well as in the time between diagnosis and the first anti-TNF dispensation (6495 mg vs 3490 mg of prednisone equivalents, P < .0001). In CD, persons diagnosed before age 18 were dispensed more corticosteroids before starting anti-TNFs (median, 4405 mg; IQR, 2000-10,885 mg) than those aged 18-40 at diagnosis (3520 mg; IQR, 1000-6370 mg; P < .05 vs age at diagnosis <18) as well as those diagnosed when 40 or older (median, 2678 mg; IQR, 520-5405 mg; P < .05 vs age at diagnosis <18). Men with CD also had greater consumption of corticosteroids between diagnosis and anti-TNF initiation than did women (men: 4150 mg; IQR, 1595-8000 mg; women: 3000 mg; IQR, 830-6225 mg; P < .019); among persons with UC, no differences in cumulative corticosteroid use were seen between the sexes or between age strata.
Corticosteroid dependence before anti-TNF initiation was seen in 72% of UC and 51% of CD patients. Among those who were corticosteroid dependent, 21.5%, 29.6%, and 40.7% of CD and 8.5%, 13.5%, and 19.6% of UC patients received an anti-TNF within 1, 2, and 5 years, respectively, of their initial episode of corticosteroid dependence. In both CD and UC, persons 40 and older at diagnosis were more likely to receive anti-TNF therapy later after becoming corticosteroid dependent than both those diagnosed at age 18-39 (P values: CD < .0001, UC ¼ .0006) and those diagnosed when 18 or younger (P values: CD ¼ .0097, UC ¼ .0028).
Time Trends, Hospitalizations, Inflammatory Bowel Disease-related Surgeries, Immunomodulator and Corticosteroid Use Before Anti-Tumor Necrosis Factor Therapy
The proportion of persons with hospitalization in the year before anti-TNF initiation did not change across eras for CD (21% in era 1, 30% in era 2, 25% in era 3; P > .2) and for UC (18% in era 2 vs 29% in era 3; P ¼ . 19 ). There was also no change in the proportion of persons with CD with a history of IBD-related surgery across the eras (40% in era 1, 37% in era 2, 35% in era 3; P > .2). Ongoing IM therapy among persons with active IM use immediately before anti-TNF initiation decreased among more recently treated cohorts with CD (82% in era 1, 68% in era 2, 58% in era 3; P < .001 for trend) and was also less prevalent among those using ADA as an initial anti-TNF therapy vs IFX (68% vs 57%; P ¼ .043). There was a significant decrease in the time to anti-TNF dispensation after IM use between those diagnosed in era 1 vs era 3 (P ¼ .0056), but all other comparisons were not significantly different ( Figure 4A ). However, there was a significant difference in the time to IM use and anti-TNF dispensation among those with UC when comparing era 2 with era 3 (P ¼ .0097, Figure 4B ), as well as in the time between onset of corticosteroid dependence and anti-TNF initiation (P ¼ .0064 via logrank test); these differences were not significantly different in CD (Figures 4C and D) .
Among persons with CD in each era who went on to receive anti-TNF, we did not detect a difference in the cumulative dose of corticosteroids within the subcohort of persons in era 1, era 2, or era 3 who received anti-TNF therapy ( Figure 5A ). In UC, there was a significant reduction in the cumulative corticosteroid exposure between persons diagnosed in era 2 and those diagnosed in era 3 ( Figure 5B ). 17 recently demonstrated in a Dutch population-based cohort that 41.8% of all persons with CD diagnosed since 2006 were exposed to anti-TNF agents within 5 years of diagnosis, compared with 3.1% for those diagnosed between 1991 and 1998. Identifying the patterns and predictors of anti-TNF use is important because of the high direct costs of biologic therapy for persons with IBD. Several economic analyses have suggested the costs of biologic therapy in the modern era exceed all other drug costs as well as those for hospitalization and surgery. Bernstein et al 18 have previously reported that anti-TNF use was responsible for more than half of all drug costs among IBD patients in 2006; a high proportional cost of biologics has also been seen in European analyses. 19 Understanding that the use of biologic therapy is increasing in time and also is being used earlier in the course of disease will assist payers in estimating the impacts of coverage of these medications on future budgets. We found that biologic use was much more common among persons diagnosed before age 18, when compared with those diagnosed between ages 18 and 39 and those diagnosed after age 40. It is recognized that persons diagnosed with IBD as children or adolescents may have a more aggressive course of disease, which likely is a major driver of the need for biologic therapy. 20, 21 However, because of the high rates of corticosteroid dependence before anti-TNF therapy, it is conceivable that increased attention to reducing corticosteroid use and/ or recognizing the need for recurrent corticosteroid use as an indication for biologic therapy may lead to even greater utilization of anti-TNF therapies in these cohorts. Surprisingly, although we were able to detect a reduction in overall corticosteroid use and in the time between either becoming corticosteroid dependent or starting IMs before anti-TNF use in UC, we did not see a statistically significant time trend effect on these outcomes among those with CD. Furthermore, symptoms of ongoing or recurrent inflammation in UC are generally easier to recognize than they are with CD 22 ; therefore, because of the secular trend toward greater utilization of anti-TNF therapy in general, clinicians may be more likely to step up to anti-TNF therapy. However, only 40.7% of persons with CD used an anti-TNF within 5 years of having evidence of corticosteroid dependence, suggesting opportunities for accessing anti-TNFs earlier in the course of disease and avoiding significant corticosteroid exposure.
Discussion
Interestingly, we did not detect any increase in concomitant IM use among persons starting biologic therapy in the more recent eras of treatment. Though Baert et al 23 first suggested the benefits of concomitant IM use for reducing infliximab-related immunogenicity, benefits of combination therapy was definitely demonstrated with the SONIC study in 2010. 7 However, we were not able to detect increased uptake in combination therapy among anti-TNF initiators. This may be related to fears about an increased risk of infectious or malignant complications with combination therapy, 24 although the benefits of combination therapy almost certainly outweigh the theoretical increased risks. Alternatively, this may represent a knowledge translation gap between evidence and practice, suggesting the need for further education and incentivization for patients and clinicians.
The major strength of this work is that it represents a large population-based cohort of persons with IBD, with longitudinal data extending from the initial release of anti-TNF medication to the recent past. As such, we are able to provide a panoramic view of the natural history of IBD in the anti-TNF era and evaluate changes in prescribing practice during that period. This study does have some noteworthy limitations. Because this data set contains only outpatient drug dispensations, it is possible that measured corticosteroid exposure may be underestimated because corticosteroids provided to inpatients would not have been counted. Conversely, persons dispensed corticosteroids may not necessarily consume every dose, which could lead to dose overestimation. This data set also does not contain data on dietary habits, tobacco exposure, and other behavioral risk factors that may also influence anti-TNF dispensation.
In summation, use of anti-TNFs has been increasing over time, and they are used earlier in the course of disease. The burden of cumulative corticosteroid use before starting anti-TNF therapy appears to be decreasing over time, suggesting that clinicians are less likely to delay the use of anti-TNFs in clinical scenarios where they are likely beneficial. However, a majority of persons with IBD do not receive anti-TNFs within 5 years of first becoming corticosteroid dependent, suggesting the need for improving quality of care in persons with IBD. Furthermore, barriers preventing the use of combination therapy in persons initiating anti-TNF drugs should be sought out to promote optimal outcomes and best practices.
